Transmission assessment surveys (TAS) to define endpoints for lymphatic filariasis mass drug administration: a multicenter evaluation.
Transmission assessment surveys (TAS) to define endpoints for lymphatic filariasis mass drug administration: a multicenter evaluation.
复制标题
DOI：
10.1371/journal.pntd.0002584
复制
发表时间：
2013
影响因子：
3.8
通讯作者：
Won KY
中科院分区：
文献类型：
--
作者：
Chu BK;Deming M;Biritwum NK;Bougma WR;Dorkenoo AM;El-Setouhy M;Fischer PU;Gass K;Gonzalez de Peña M;Mercado-Hernandez L;Kyelem D;Lammie PJ;Flueckiger RM;Mwingira UJ;Noordin R;Offei Owusu I;Ottesen EA;Pavluck A;Pilotte N;Rao RU;Samarasekera D;Schmaedick MA;Settinayake S;Simonsen PE;Supali T;Taleo F;Torres M;Weil GJ;Won KY
淋巴丝虫病(LF)的目标是通过重复每年大规模给药(MDA)治疗整个高危人群，从而在全球范围内消除这种疾病。项目成功的关键是确定和确定适当的丙二醛终点，此时丙二醛的传播被推定到足够低的水平，即使在没有药物干预的情况下也无法维持。世卫组织提出的指南要求进行传播评估调查(TAS)，以确定在至少五轮有效的年度治疗后，丙二醛是否可以在LF评估单位(EU)内停止。为了测试这些指南的价值和实用性，在11个国家进行了一项涵盖各种地理和流行病学环境的多中心业务研究试验。TAS-1和TAS-2在每个欧盟进行了两次，相隔约24个月。批量质量保证抽样(LQAS)构成了TAS调查设计的基础，但欧盟的具体特点定义了调查地点(学校或社区)、合格人口(6-7岁或一年级)、调查类型(系统抽样或整群抽样)、目标样本量和临界截止点(低于这个临界值，传播预计不再可持续)。主要的诊断工具是免疫层析(ICT)检测班氏丝虫EU和BmR1检测(快速布鲁氏菌或PanLF)布鲁氏菌。尤斯。在11个EU中，有10个的TAS-1阳性病例数低于临界值，表明丙二醛可以停止。在随访的TAS-2中也发现了相同的结果，因此，证实了先前的决定结果。样本大小具有高度的性别和年龄代表性，在考虑到不参与的估计后，样本量与目标值非常接近。TAS被确定为阻止丙二醛的实用和有效的评估工具，尽管其对丙二醛后较长期监测的有效性需要进一步调查。淋巴丝虫病(LF)的目标是通过对整个高危人群重复每年大规模给药(MDA)的战略，在全球范围内消除淋巴丝虫病。传播评估调查(TAS)旨在评估LF的传播是否被推定到足够低的水平，以至于在没有药物干预的情况下无法持续，从而可以阻止丙二醛。这项多中心业务研究试验通过在11个地理和流行病学特征不同的国家实施《技术援助准则》，检验了该准则的价值和实用性。实地经验支持了TAS的调查设计方法，特别是在学校和基于分组的抽样战略方面。我们发现，样本大小具有年龄和性别代表性，在考虑了不参与率的估计后，达到了目标值。在11个国家中的10个国家，TAS发现评价单位的阳性病例数不超过统计学上的临界阈值。这些结果在大约24个月后的随访TAS中得到证实。我们的结论是，TAS是阻止丙二醛的有价值和有效的工具，但其对丙二醛后较长期监测的有效性需要进一步的经验证据，并可能最好地得到补充工具和方法的支持。
Lymphatic filariasis (LF) is targeted for global elimination through treatment of entire at-risk populations with repeated annual mass drug administration (MDA). Essential for program success is defining and confirming the appropriate endpoint for MDA when transmission is presumed to have reached a level low enough that it cannot be sustained even in the absence of drug intervention. Guidelines advanced by WHO call for a transmission assessment survey (TAS) to determine if MDA can be stopped within an LF evaluation unit (EU) after at least five effective rounds of annual treatment. To test the value and practicality of these guidelines, a multicenter operational research trial was undertaken in 11 countries covering various geographic and epidemiological settings. The TAS was conducted twice in each EU with TAS-1 and TAS-2 approximately 24 months apart. Lot quality assurance sampling (LQAS) formed the basis of the TAS survey design but specific EU characteristics defined the survey site (school or community), eligible population (6–7 year olds or 1st–2nd graders), survey type (systematic or cluster-sampling), target sample size, and critical cutoff (a statistically powered threshold below which transmission is expected to be no longer sustainable). The primary diagnostic tools were the immunochromatographic (ICT) test for W. bancrofti EUs and the BmR1 test (Brugia Rapid or PanLF) for Brugia spp. EUs. In 10 of 11 EUs, the number of TAS-1 positive cases was below the critical cutoff, indicating that MDA could be stopped. The same results were found in the follow-up TAS-2, therefore, confirming the previous decision outcome. Sample sizes were highly sex and age-representative and closely matched the target value after factoring in estimates of non-participation. The TAS was determined to be a practical and effective evaluation tool for stopping MDA although its validity for longer-term post-MDA surveillance requires further investigation. Lymphatic filariasis (LF) is targeted for global elimination through a strategy of repeated annual mass drug administration (MDA) to entire at-risk populations. A transmission assessment survey (TAS) is designed to evaluate whether transmission of LF is presumed to have reached a level low enough that it cannot be sustained in the absence of drug intervention and, therefore, MDA can be stopped. This multicenter operational research trial examines the value and practicality of the TAS guidelines through its implementation in 11 countries of diverse geographical and epidemiologic profiles. The field experiences support the TAS survey design methodology with particular respect to school and cluster-based sampling strategies. We found that sample sizes were age and sex representative and met the target values after factoring in estimates of non-participation rates. In 10 of 11 countries, the TAS found the number of positive cases in the evaluation unit to be no more than the statistically powered critical threshold. These results were corroborated in a follow-up TAS approximately 24 months later. We conclude the TAS is a valuable and effective tool for stopping MDA but its utility for longer-term post-MDA surveillance needs further empirical evidence and may be best supported with complementary tools and methods.
登录
查看更多内容
影响因子：
3.8
作者：
Ottesen, Eric A.;Hooper, Pamela J.;Biswas, Gautam
通讯作者：
Biswas, Gautam
DOI：
10.4269/ajtmh.2007.76.502
发表时间：
2007-03-01
影响因子：
3.3
作者：
Fischer, Peter;Erickson, Sara M.;Weil, Gary J.
通讯作者：
Weil, Gary J.
影响因子：
3.8
作者：
Gass K;Beau de Rochars MV;Boakye D;Bradley M;Fischer PU;Gyapong J;Itoh M;Ituaso-Conway N;Joseph H;Kyelem D;Laney SJ;Legrand AM;Liyanage TS;Melrose W;Mohammed K;Pilotte N;Ottesen EA;Plichart C;Ramaiah K;Rao RU;Talbot J;Weil GJ;Williams SA;Won KY;Lammie P
通讯作者：
Lammie P
DOI：
10.1186/1475-2883-6-9
发表时间：
2007-10-26
期刊：
Filaria journal
影响因子：
--
作者：
Noordin, Rahmah;Itoh, Makoto;Weerasooriya, Mirani
通讯作者：
Weerasooriya, Mirani
DOI：
10.4269/ajtmh.2011.10-0610
发表时间：
2011-06-01
影响因子：
3.3
作者：
Mathieu, Els;Dorkenoo, Ameyo;Sodahlon, Yao K.
通讯作者：
Sodahlon, Yao K.